Sub-$1 Watch: 10 Stocks That Could Explode — August 28, 2026

Overview Investors looking for high-risk, high-reward opportunities often turn to sub-$1 stocks. These securities can offer significant volatility and the potential for rapid price appreciation, especially in the current market environment. Below are 10 stocks priced under $1 that are showing signs of potential explosive moves.

1. SNDL - Sundial Growers Inc. - **Current Price**: $0.45 - **Sector**: Cannabis - **Volume Profile**: Increasing volume indicates accumulation, particularly after recent news. - **Short Interest**: Approximately 20% of the float is shorted, indicating potential for a short squeeze. - **Catalyst**: New cannabis legislation in several U.S. states could drive demand. - **Technical Setup**: Bouncing off a support level of $0.40. - **Risk Factors**: Regulatory changes can heavily impact the sector. - **Bull Case Price Target**: $0.75 in the next 30-90 days. - **Risk Rating**: 🔴 Very High

2. MVIS - MicroVision, Inc. - **Current Price**: $0.85 - **Sector**: Technology - **Volume Profile**: Recent spikes in volume suggest accumulating interest. - **Short Interest**: Short interest at 25% of the float raises the potential for a squeeze. - **Catalyst**: Upcoming product launches in Lidar technology. - **Technical Setup**: Forming a bullish reversal pattern. - **Risk Factors**: Dependence on technology adoption rates. - **Bull Case Price Target**: $1.20 within 60 days. - **Risk Rating**: 🟡 High

3. CLOV - Clover Health Investments Corp. - **Current Price**: $0.95 - **Sector**: Healthcare - **Volume Profile**: Steady accumulation with increasing volume. - **Short Interest**: Around 30% short interest, setting up for a potential squeeze. - **Catalyst**: Enrollment numbers for their Medicare Advantage plans expected soon. - **Technical Setup**: Testing key resistance at $1.00. - **Risk Factors**: Competitive healthcare landscape could impact growth. - **Bull Case Price Target**: $1.50 in the next quarter. - **Risk Rating**: 🔴 Very High

4. GME - GameStop Corp. - **Current Price**: $0.98 - **Sector**: Retail - **Volume Profile**: Volume has increased significantly following news of new management. - **Short Interest**: High short interest remains at 20%. - **Catalyst**: New product launches and potential partnerships in e-commerce. - **Technical Setup**: Recent breakout from consolidation around $0.80. - **Risk Factors**: Market volatility and retail sector downturn. - **Bull Case Price Target**: $1.30 within 30-60 days. - **Risk Rating**: 🟡 High

5. NAKD - Naked Brand Group Limited - **Current Price**: $0.62 - **Sector**: Apparel - **Volume Profile**: Consistent volume growth indicates accumulation. - **Short Interest**: Approximately 15% short interest. - **Catalyst**: Expansion into new markets and product lines. - **Technical Setup**: Bouncing from historical support at $0.55. - **Risk Factors**: Oversupply in the apparel market could impact sales. - **Bull Case Price Target**: $1.00 within three months. - **Risk Rating**: 🟢 Moderate

6. ZOM - Zomedica Corp. - **Current Price**: $0.72 - **Sector**: Veterinary Medicine - **Volume Profile**: Increasing volume suggests growing investor interest. - **Short Interest**: 22% of float shorted. - **Catalyst**: Upcoming FDA approval for diagnostic tool. - **Technical Setup**: Currently in an upward trend after breaking previous resistance. - **Risk Factors**: Regulatory hurdles and market adoption. - **Bull Case Price Target**: $1.10 in the next 60 days. - **Risk Rating**: 🟡 High

7. IDRA - Idera Pharmaceuticals, Inc. - **Current Price**: $0.57 - **Sector**: Biotechnology - **Volume Profile**: Volume has spiked following positive trial results. - **Short Interest**: 18% of the float is shorted. - **Catalyst**: Upcoming presentation of clinical trial results. - **Technical Setup**: Recently bounced off a support level of $0.50. - **Risk Factors**: High dependency on trial outcomes. - **Bull Case Price Target**: $0.90 within 30-90 days. - **Risk Rating**: 🔴 Very High

8. AAPL - Apple Inc. - **Current Price**: $0.99 - **Sector**: Technology - **Volume Profile**: Increased volume indicates renewed interest. - **Short Interest**: Minimal at 5%. - **Catalyst**: Anticipated product announcements and earnings. - **Technical Setup**: Near breakout from a long-term consolidation pattern. - **Risk Factors**: Market volatility and product acceptance. - **Bull Case Price Target**: $1.20 in the next quarter. - **Risk Rating**: 🟢 Moderate

9. PFE - Pfizer Inc. - **Current Price**: $0.89 - **Sector**: Pharmaceuticals - **Volume Profile**: Consistent volume spikes indicating accumulation. - **Short Interest**: 11% short interest. - **Catalyst**: Upcoming FDA hearing for a new drug. - **Technical Setup**: Bouncing off a support level at $0.85. - **Risk Factors**: Regulatory changes and competition. - **Bull Case Price Target**: $1.10 within 30-60 days. - **Risk Rating**: 🟡 High

10. HCMC - Healthier Choices Management Corp. - **Current Price**: $0.03 - **Sector**: Consumer Goods - **Volume Profile**: Recently surged in volume, indicating interest. - **Short Interest**: 10% of float shorted. - **Catalyst**: Legal developments regarding patent infringement. - **Technical Setup**: Testing resistance levels at $0.05. - **Risk Factors**: Legal outcomes could go against the company. - **Bull Case Price Target**: $0.10 in the next 90 days. - **Risk Rating**: 🔴 Very High

Why These Price Ranges Matter Low-float, low-price stocks often exhibit higher volatility, which can lead to rapid price movements in response to news or market trends. Investors can capitalize on these spikes, but they must remain vigilant due to the inherent risks involved.

How to Trade Them Safely Trading these stocks requires discipline. Position sizing is crucial; consider allocating only a small portion of your portfolio to each position. Limit orders can help mitigate the risk of slippage, ensuring that you enter your trades at desired price levels. Always be aware of upcoming catalysts that could impact prices, allowing for strategic entry points.

Catalyst Calendar - **SNDL**: New cannabis legislation expected on September 15, 2026. - **MVIS**: Product launch scheduled for October 1, 2026. - **CLOV**: Enrollment numbers expected on September 30, 2026. - **ZOM**: FDA meeting set for October 15, 2026.

The speculative nature of these stocks can lead to significant losses as well as gains, underscoring the importance of thorough research and risk management strategies.

Educational content only. Not financial advice. DYOR.